# Sulfasalazine in Patients With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06134388/  
OnCo record `nct06134388` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Tanta University, now recruiting.

## Summary

Sulfasalazine in Patients With Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT06134388 by Tanta University, with a registry enrolment figure of 50 participants, started 2023-09-01 and due to reach its primary completion in 2025-09. Interventions recorded: Sulfasalazine. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Evaluating the change in the serum level of Ferritin; Evaluating the change in the serum level of Superoxide dismutase (SOD); Evaluating the change in the serum level of Nuclear factor-kappa B (NF-kB). Colorectal eligibility wording from the registry: "Histologically confirmed diagnosis of stage IV (metastatic) colorectal cancer". Sites: Egypt. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06134388
- Phase: 3
- Setting: Clinical Study Evaluating the Efficacy and Safety of Sulfasalazine in Patients With Metastatic Colorectal Cancer
- Sponsor: Tanta University
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06134388: https://clinicaltrials.gov/study/NCT06134388

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06134388.json